Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box
Paolo Tarantino, Aleix Prat, Javier Cortés, Fátima Cardoso, Giuseppe Curigliano
Topics & Concepts
NeratinibTrastuzumabMedicineClinical trialOncologyBreast cancerInternal medicineRandomized controlled trialPopulationHuman Epidermal Growth Factor Receptor 2DrugCancerPharmacologyEnvironmental healthHER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies ResearchAdvanced Breast Cancer Therapies